Cefoperazone: Difference between revisions
No edit summary |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 25: | Line 25: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
| Line 33: | Line 33: | ||
''Cefina-SB'' is a combination of [[sulbactam]] and cefoperazone. Cefoperazone exerts its bactericidal effect by inhibiting the [[bacterial]] [[cell wall]] synthesis, and sulbactam acts as a beta-lactamase inhibitor, to increase the antibacterial activity of cefoperazone against beta-lactamase producing organisms. Cefina-SB is available as injection for the treatment of bacterial infections. In some countries, the combination is sold as ''Sulperazone''. Cefoperazone is available in the United States as Cefobid. | ''Cefina-SB'' is a combination of [[sulbactam]] and cefoperazone. Cefoperazone exerts its bactericidal effect by inhibiting the [[bacterial]] [[cell wall]] synthesis, and sulbactam acts as a beta-lactamase inhibitor, to increase the antibacterial activity of cefoperazone against beta-lactamase producing organisms. Cefina-SB is available as injection for the treatment of bacterial infections. In some countries, the combination is sold as ''Sulperazone''. Cefoperazone is available in the United States as Cefobid. | ||
{{CephalosporinAntiBiotics}} | {{CephalosporinAntiBiotics}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 23:36, 8 August 2012
{{drugbox
| IUPAC_name = (6R,7S)-7-{[2-[(4-ethyl-2,3-dioxo-piperazine-1-
carbonyl)amino]-2-(4-hydroxyphenyl)acetyl}amino]-
3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Cefoperazone.svg
| CAS_number = 62893-19-0
| ATC_prefix = J01
| ATC_suffix = DD12
| ATC_supplemental = J01DD62 (WHO)
| PubChem = 44185
| DrugBank =
| C=25|H=27|N=9|O=8|S=2
| molecular_weight = 645.67 g/mol
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category=
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
}}
|
WikiDoc Resources for Cefoperazone |
|
Articles |
|---|
|
Most recent articles on Cefoperazone Most cited articles on Cefoperazone |
|
Media |
|
Powerpoint slides on Cefoperazone |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cefoperazone at Clinical Trials.gov Clinical Trials on Cefoperazone at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cefoperazone
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cefoperazone Discussion groups on Cefoperazone Patient Handouts on Cefoperazone Directions to Hospitals Treating Cefoperazone Risk calculators and risk factors for Cefoperazone
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cefoperazone |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Cefoperazone is a third generation cephalosporin antibiotic. Marketed by pfizer under the name Cefobid®.
Cefina-SB is a combination of sulbactam and cefoperazone. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis, and sulbactam acts as a beta-lactamase inhibitor, to increase the antibacterial activity of cefoperazone against beta-lactamase producing organisms. Cefina-SB is available as injection for the treatment of bacterial infections. In some countries, the combination is sold as Sulperazone. Cefoperazone is available in the United States as Cefobid.